U.S. FDA approves Pfizer's high profile breast cancer drug
February 03, 2015 at 16:09 PM EST
Feb 3 (Reuters) - The U.S. Food and Drug Administration on Tuesday said it had approved Pfizer Inc's experimental breast cancer drug Ibrance, a regulatory decision that came more than two months earlier than expected.
